FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle

1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest

800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle

25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle